Atovaquone

Therapeutic indications

Atovaquone is indicated for:

Mild to moderate pneumocystis pneumonia caused by Pneumocystis jiroveci

Population group: both men and women, only adults (18 - 65 years old)

Atovaquone is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP, caused by Pneumocystis jiroveci, formerly classified as P. carinii) (alveolar – arterial oxygen tension difference [(A-a) DO2] ≤45 mmHg (6 kPa) and oxygen tension in arterial blood (PaO2) ≥60 mmHg (8 kPa) breathing room air) in patients who are intolerant of co-trimoxazole therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1500 mg in 2 divided doses daily

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines